SPAG5 and breast cancer: Also in our study, RFS, OS and DMFS were better in TP53 wild-type breast carcinomas patients with low-expressed SPAG5, while the survival curves did not show a significant difference in the survival outcomes of TP53-mutated breast cancer patients.